MediBeacon is a medical technology company focused on advancing the use of fluorescent tracer agents and transdermal detection technology to provide vital and actionable measurement of organ function. New insights that have direct relevance to treatment decisions are the goal.
Accurate physiological measurements made at the point of care can be of utmost value in the critical care setting as well as in the management of chronic diseases. The opportunities to use this data to help improve disease treatments in situations where multiple unknowns make clinical decisions a challenge are vast.
In October of 2018 the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). The device is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function.
Accurate physiological measurements made in real-time and at the point of care could be of utmost value in the critical care setting as well as in the management of chronic diseases. Fluorescent tracer agent-based monitoring systems are designed to be well positioned to provide measured GFR, GI permeability quantification, enhanced visualization of the vasculature during ocular angiography, and identification of the ureters during abdominal surgeries.*